Australia PBS Seeks To Lower High Cost Of BMS Melanoma Drug
This article was originally published in PharmAsia News
Australia's Pharmaceutical Benefits Scheme is attempting to negotiate with Bristol Myers Squibb to lower the price of its Yervoy (ipilimumab) so melanoma patients can afford it.
You may also be interested in...
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.
US FDA’s latest effort to provide guidance for consumers on pharmacogenomics tests underscores the challenges the agency faces in the absence of a clear regulatory framework for lab-developed tests – and with no easy mechanism to update labels for off-patent drugs.